Cover Image

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study

BackgroundThe 5-year event-free survival rate for childhood acute lymphoblastic leukemia (ALL) has increased to more than 85%. However, the 5-year overall survival rate in children with relapsed/refractory ALL did not exceed 50%. In the past decade, immunotherapies (such as blinatumomab and chimeric...

Full description

Saved in:

Bibliographic Details
Main Authors:	Songmi Wang (Author), Aiguo Liu (Author), Na Wang (Author), Yaqin Wang (Author), Ai Zhang (Author), Li Wang (Author), Wen Yu (Author), Chunrui Li (Author), Yicheng Zhang (Author), Qun Hu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
by: Jiao Xie, et al.
Published: (2023)

Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis
by: Bin Chen, et al.
Published: (2023)

Blinatumomab as a Curative Therapy Option for Relapsed/Refractory Infant Acute Lymphoblastic Leukemia Post-Hematopoietic Stem Cell Transplantation - Case Report
by: Suleimen Zhumatayev, et al.
Published: (2024)

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
by: Alexander Russell-Smith, et al.
Published: (2023)

Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
by: Yadan Liu, et al.
Published: (2021)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
by: Vairy S, et al.
Published: (2018)

Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
by: Ying Wu, et al.
Published: (2022)

Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia
by: Wenxiu Lv, et al.
Published: (2023)

Corrigendum: Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
by: Ying Wu, et al.
Published: (2022)

Effects of CAR-T Cell Therapy on Immune Cells and Related Toxic Side Effect Analysis in Patients with Refractory Acute Lymphoblastic Leukemia
by: Lianlian Li, et al.
Published: (2023)

Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials
by: Xinrong Xiang, et al.
Published: (2020)

Case report: A case of acquired von Willebrand syndrome as onset clinical presentation of systemic lupus erythematosus manifested as epistaxis and pulmonary hemorrhage
by: Songmi Wang, et al.
Published: (2022)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
by: Lee KJ, et al.
Published: (2016)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
by: Le Jeune C, et al.
Published: (2016)

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
by: Hai-ping Dai, et al.
Published: (2022)

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
by: Forsberg MH, et al.
Published: (2018)

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
by: Portell CA, et al.
Published: (2013)

Blinatumomab-associated vasculitis
by: MeiQi May Liau, MBChB, MRCP (UK), et al.
Published: (2017)

Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report
by: Meng-Yun Li, et al.
Published: (2020)

Clinical analysis of immune reconstitution after chemotherapy in children with acute lymphoblastic leukemia
by: Yuting Xu, et al.
Published: (2024)

Successful treatment of acute B lymphoblastic leukemia relapse in the skin and testicle by anti-CD19 CAR-T with IL-6 knocking down: a case report
by: Ze-Fa Liu, et al.
Published: (2020)

The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis
by: Maria Maddalena Marrapodi, et al.
Published: (2022)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
by: Sandrine Niyongere, et al.
Published: (2020)

Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia
by: Yamini K. Kathari, et al.
Published: (2024)

Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations
by: Caio Bezerra Machado, et al.
Published: (2021)

Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone
by: Wenqian Wang, et al.
Published: (2024)

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas
by: Pedro Justicia-Lirio, et al.
Published: (2024)

DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
by: Xin Wang, et al.
Published: (2021)

A case of B-cell lymphoblastic leukemia cutis flaring following CAR T-cell therapy in a patient with refractory acute lymphoblastic leukemia
by: Pranav Puri, BA, et al.
Published: (2021)

Relapsed childhood acute lymphoblastic leukemia: Current situation in China; a multicenter observational study
by: Qun Hu, et al.
Published: (2018)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
by: Xiwen Tong, et al.
Published: (2023)

Toxicity profile and outcomes of salvage chemotherapy regimens in children and adolescents with relapsed/refractory acute myeloid leukemia
by: Maharshi Trivedi, et al.
Published: (2024)

Beyond CD19: Opportunities for future development of targeted immunotherapy in pediatric relapsed-refractory acute leukemia
by: Haneen eShalabi, et al.
Published: (2015)

Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
by: Wang XJ, et al.
Published: (2022)

Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
by: Zhao F, et al.
Published: (2018)

Novel Therapies for Relapsed and Refractory Neuroblastoma
by: Peter E. Zage
Published: (2018)

Drug response profiling identifies sensitive synergistic drug combinations for patients with refractory/relapsed acute lymphoblastic leukemia
by: Jasmeet Sidhu, et al.
Published: (2022)

Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era
by: Shang Mengxuan, et al.
Published: (2022)

Pediatric-onset refractory relapsing polychondritis with respiratory tract involvement
by: Yuh-Jue Chen, et al.
Published: (2021)

Case Report: Is Surgical Treatment Beneficial for Intracranial Basal Ganglia Cunninghamellamycosis Following Haematopoietic Stem Cell Transplantation?
by: Bixin Xi, et al.
Published: (2022)